Dennis Wright - Realord Group Vice President - Scientific Affairs
| CUV Stock | EUR 0.84 0.02 2.33% |
President
Dr. Dennis J. Wright, BPharm, MSc, Ph.D., serves as Acting Chief Scientific Officer of Clinuvel Pharmaceuticals Ltd since September 2012. He was previously Vice President Scientific Affairs of the Company. Dr. Wright has a range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager. Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen . He has a Pharmacy degree and postgraduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne since 2012.
| Tenure | 12 years |
| Phone | 852 3959 2888 |
| Web | https://www.realord.com.hk |
Realord Group Management Efficiency
Realord Group's management efficiency ratios could be used to measure how well Realord Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Steven Bruny | Ribbon Communications | 61 | |
| Kevin Riley | Ribbon Communications | 48 | |
| Miguel Lopez | Ribbon Communications | 63 | |
| Thomas Appio | Bausch Health Companies | 61 | |
| Anthony Scarfo | Ribbon Communications | 62 | |
Management Performance
| Return On Equity | 0.0546 | |||
| Return On Asset | -0.005 |
Realord Group Holdings Leadership Team
Elected by the shareholders, the Realord Group's board of directors comprises two types of representatives: Realord Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Realord. The board's role is to monitor Realord Group's management team and ensure that shareholders' interests are well served. Realord Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Realord Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Smith, Non-Executive Director | ||
| Madam Su, CEO Director | ||
| Xiaodong Lin, Ex Director | ||
| Willem Blijdorp, Non-Executive Chairman of the Board | ||
| Jeffrey Rosenfeld, Non-Executive Director | ||
| Philippe Wolgen, Chief Executive Officer, Managing Director, Executive Director | ||
| Karen Agersborg, Non-Executive Director | ||
| Chin Tsang, CFO Sec | ||
| Darren Keamy, Chief Financial Officer, Company Secretary | ||
| Xiaohui Lin, Ex Chairman | ||
| Dennis Wright, Vice President - Scientific Affairs | ||
| Brenda Shanahan, Non-Executive Independent Director |
Realord Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Realord Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0546 | |||
| Return On Asset | -0.005 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 2.93 B | |||
| Shares Outstanding | 1.44 B | |||
| Shares Owned By Insiders | 73.34 % | |||
| Shares Owned By Institutions | 1.37 % | |||
| Price To Earning | 16.21 X | |||
| Price To Book | 3.20 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Realord Stock
Realord Group financial ratios help investors to determine whether Realord Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Realord with respect to the benefits of owning Realord Group security.